Roche's arthritis drug Actemra reaches goal in 2nd phase III study |
|
|
|
Published
:
Wed, 06 Jun 2007 08:52
|
ZURICH (Thomson Financial) - Roche Holdings AG said rheumatoid arthritis drug Actemra has successfully reached its goal in a multinational phase III study, with patients achieving a 'significant improvement' in symptoms.The pharma group said a greater proportion of patients treated with Actemra in combination with traditional disease modifying drugs (DMARDS) achieved a significant improvement after 24 weeks, compared to those treated with DMARDS alone.A total of 1,216 patients with moderate to severe rheumatoid arthritis participated in the phase III study, which is the second in a programme of five phase III clinical trials currently running on Actemra.In January, Roche reported that Actemra was more effective than methorexate according to data from its first phase III trial of the drug outside Japan.sarah.fenwick@thomson.comsf/cwCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
1617.01 |
+17.95 (
1.13 %)
|
| SYMBOL (
2009-01-08 ) |
| LAST |
CHANGE
|
| SYMBOL (
2009-01-08 )
|
| LAST |
CHANGE
|
| SYMBOL (
2009-01-08 )
|
| LAST |
CHANGE
|
|
|
Print this Story
Japan's Chugai Pharma not to co-promote arthritis treatment in US, Italy, Spain 